Incorporation of antigens into viral capsids augments immunogenicity of adeno-associated virus vector-based vaccines

Journal of Virology

Volumn 86, Issue 24, 2012, Pages 13800-13804

  Rybniker, Jan ^a   Nowag, Angela ^a   Janicki, Hanna ^a,b   Demant, Kai ^a   Hartmann, Pia ^a   Büning, Hildegard ^a,b  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN 85A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M; PARVOVIRUS VECTOR; PROTEIN VP1; PROTEIN VP2; PROTEIN VP3; UNCLASSIFIED DRUG; VIRUS ANTIGEN; VIRUS VACCINE;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ANTIBODY TITER; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; BINDING AFFINITY; DNA MODIFICATION; DRUG POTENCY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE OVEREXPRESSION; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; MOLECULAR CLONING; NONHUMAN; PRIORITY JOURNAL; SEROTYPE; START CODON; VIRAL TROPISM; VIRUS ASSEMBLY; VIRUS CAPSID; VIRUS INFECTIVITY; VIRUS PARTICLE;

ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CAPSID; DEPENDOVIRUS; GENETIC VECTORS; VIRAL VACCINES;

ADENO-ASSOCIATED VIRUS; MIRIDAE;

EID: 84870673792     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01708-12     Document Type: Article

References (19)

1. Asokan A, Johnson JS, Li C, Samulski RJ. 2008. Bioluminescent virion shells: new tools for quantitation of AAV vector dynamics in cells and live animals. Gene Ther. 15:1618-1622.
2. Boucas J, et al. 2009. Engineering adeno-associated virus serotype 2-based targeting vectors using a new insertion site-position 453- and single point mutations. J. Gene Med. 11:1103-1113.
3. Buning H, Perabo L, Coutelle O, Quadt-Humme S, Hallek M. 2008. Recent developments in adeno-associated virus vector technology. J. Gene Med. 10:717-733.
4. Ferreira MU, Katzin AM. 1995. The assessment of antibody affinity distribution by thiocyanate elution: a simple dose-response approach. J. Immunol. Methods 187:297-305.
5. Hacker UT, et al. 2005. Adeno-associated virus serotypes 1 to 5 mediated tumor cell directed gene transfer and improvement of transduction efficiency. J. Gene Med. 7:1429-1438.
6. Hamkar R, et al. 2005. Assessment of IgM enzyme immunoassay and IgG avidity assay for distinguishing between primary and secondary immune response to rubella vaccine. J. Virol. Methods 130:59-65.
7. Huygen K, et al. 1996. Immunogenicity and protective efficacy of a tuberculosis DNA vaccine. Nat. Med. 2:893-898.
8. Lin J, et al. 2009. A new genetic vaccine platform based on an adenoassociated virus isolated from a rhesus macaque. J. Virol. 83:12738-12750.
9. Logan GJ, Wang L, Zheng M, Coppel RL, Alexander IE. 2010. Antigen fusion with C3d3 augments or inhibits humoral immunity to AAV genetic vaccines in a transgene-dependent manner. Immunol. Cell Biol. 88:228-232.
10. Lux K, et al. 2005. Green fluorescent protein-tagged adeno-associated virus particles allow the study of cytosolic and nuclear trafficking. J. Virol. 79:11776-11787.
11. Mingozzi F, High KA. 2011. Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat. Rev. Genet. 12:341-355.
12. Munch RC, et al. 2012. Displaying high-affinity ligands on adenoassociated viral vectors enables tumor cell-specific and safe gene transfer. Mol. Ther. [Epub ahead of print.] doi:10.1038/mt.2012.186.
13. Pullen GR, Fitzgerald MG, Hosking CS. 1986. Antibody avidity determination by ELISA using thiocyanate elution. J. Immunol. Methods 86: 83-87.
14. Romano M, et al. 2006. Priming but not boosting with plasmid DNA encoding mycolyl-transferase Ag85A from Mycobacterium tuberculosis increases the survival time of Mycobacterium bovis BCG vaccinated mice against low dose intravenous challenge with M. tuberculosis H37Rv. Vaccine 24:3353-3364.
15. Steiner LA, Eisen HN. 1967. The relative affinity of antibodies synthesized in the secondary response. J. Exp. Med. 126:1185-1205.
16. Steiner LA, Eisen HN. 1967. Sequential changes in the relative affinity of antibodies synthesized during the immune response. J. Exp. Med. 126: 1161-1183.
17. Warrington KH, Jr, et al. 2004. Adeno-associated virus type 2 VP2 capsid protein is nonessential and can tolerate large peptide insertions at its N terminus. J. Virol. 78:6595-6609.
18. Wobus CE, et al. 2000. Monoclonal antibodies against the adenoassociated virus type 2 (AAV-2) capsid: epitope mapping and identification of capsid domains involved in AAV-2-cell interaction and neutralization of AAV-2 infection. J. Virol. 74:9281-9293.
19. Xiao X, Li J, Samulski RJ. 1998. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J. Virol. 72: 2224-2232.